Plain-English translation of NCT07799519 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help prevent atrial fibrillation (an irregular heartbeat) from returning after you have a catheter ablation procedure. Half of participants will receive daily for a year after their ablation, while the other half will receive standard care alone. Researchers will also study how this medication affects the fatty tissue around your heart and measure blood markers that may help predict who benefits most.
Even after a successful ablation procedure, atrial fibrillation often comes back in many patients. This trial is testing whether this medication might help reduce recurrence by changing the heart's fatty tissue and reducing inflammation, potentially offering a better long-term outcome for people with irregular heartbeat.
You likely qualify if…
You likely don't qualify if…
After your ablation procedure, you will be randomly assigned to either take the medication daily or receive standard care only. Over the next 12 months, you will have follow-up visits at 2 weeks, 1 month, 3 months, 6 months, 9 months, and 12 months. During this time, you'll have heart rhythm monitoring (including portable heart monitors), heart imaging tests, and blood draws to measure how well the treatment is working and how your heart's tissue is changing.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
Taiwan